Ocuphire Pharma Investor Presentation Deck

9 Secondary Endpoint: Intermediate Vision Nyxol + LDP Had Significant Improvement in Letters Read in DCIVA Compared to Placebo Change In Letters Read From Baseline (Letters Read) 12 10 8 p<0.05 6 2 0 Change from Baseline in Binocular Photopic DCIVA (Letters Read) p=<0.0001 VEGA-1 Phase 2 Trial 1 2 p<0.05 3 Time (Hours) Placebo (n=43) Nyxol+LDP (n=43) Intermediate Vision Efficacy with Nyxol+LDP 4 LO 5 Source: VEGA-1 TLR Table 14.2.7.1 Observed Values and Change from Baseline in Photopic DCIVA by Time Point (Letters Read) (PP Population) p<0.05 6 Ocuphire PHARMA

View entire presentation